BCM
OMED

BlueCrest Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

BlueCrest Capital Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14,275
Closed -$45K – 2102
2018
Q1 		$45K Sell
14,275
-18,107
-56% -$49.9K ﹤0.01% 1425
2017
Q4 		$133K Buy
+32,382
New +$141K ﹤0.01% 746

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BlueCrest Capital Management's OMED Position: Q2 2018 in Review

BlueCrest Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2018, closing a stake of 14,275 shares — an estimated $45K sold.

BlueCrest Capital Management first reported a position in OMED in Q4 2017 and held it in 2 quarters. The position peaked at $133K in Q4 2017. 63 funds tracked by Wall St. Rank hold OMED as of Q2 2018.

  • BlueCrest Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 14,275 OncoMed Pharmaceuticals, Inc. shares in Q2 2018, an estimated $45K.
  • BlueCrest Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $133K in Q4 2017.
  • 63 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.